Recent studies have looked at the use of intermittent androgen deprivation therapy (ADT) as a way to spare prostate cancer (PCa) patients some of the adverse effects associated with continuous ADT.

Study findings presented at the American Urological Association 2012 annual meeting found that intermittent ADT was associated with improved overall and PCa-specific survival in elderly men with advanced disease. But data presented at the American Society of Clinical Oncology 2012 annual meeting showed that while intermittent ADT has some quality-of-life benefits for men with metastatic PCa, overall survival times are inferior to those seen with continuous ADT.

Renal & Urology News would like to get an idea of the extent to which urologists are using intermittent ADT, so please take a few moments to answer the following question:

Continue Reading

Have you ever placed a prostate cancer patient on intermittent rather than continuous androgen deprivation therapy?
Leave a comment below to explain your choice.